MedTrace Logo

Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis

NCT00563524 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2024-08-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess safety, and tolerability of multiple doses of ILV-094 administered to subjects with psoriasis

Conditions

Interventions

DRUG

ILV-094

SC and IV administration on days 1, 14, 28, and 42

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-20
Primary Completion
2010-06-14
Completion
2010-06-14

Countries

  • United States
  • Canada
  • Hong Kong
  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00563524 on ClinicalTrials.gov